Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IVT 8086

Next Previous
X
Search
Drug Profile

IVT 8086

Alternative Names: IVT-8086

Latest Information Update: 15 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innova Therapeutics
  • Developer Innova Therapeutics; Medical University of South Carolina
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteosarcoma

Most Recent Events

  • 24 Sep 2020 Innova Therapeutics files a new drug application (NDA) for Osteosarcoma in USA, prior to September 2020
  • 24 Sep 2020 Innova Therapeutics receives rare paediatric disease designation for IVT 8086 from the US FDA for Osteosarcoma in USA
  • 24 Sep 2020 Pharmacodynamics and adverse events data from preclinical trials in Osteosarcoma released by Innova Therapeutics, prior to September 2020 (Innova Therapeutics website, September 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top